DOCSLIB.ORG

Specialty Medications That Unitypoint at Home Specialty Pharmacy Can Provide Or Facilitate Access to and Is Subject to Change

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialty Medications That Unitypoint at Home Specialty Pharmacy Can Provide Or Facilitate Access to and Is Subject to Change UnityPoint at Home Specialty Pharmacy Formulary This is a listing by therapy of specialty medications that UnityPoint at Home Specialty Pharmacy can provide or facilitate access to and is subject to change £Infusion Product – may be provided by UnityPoint at Home Infusion Pharmacy CARDIOLOGY ENDOCRINOLOGY (cont’d) GASTROENTEROLOGY (cont’d) ANTILIPIDEMICS GROWTH DEFICIENCY HEPATITIS B Praluent® (Alirocumab) Genotropin® (Somatropin) Baraclude® (Entecavir) Repatha® (Evolocumab) Humatrope® (Somatropin) Epivir HBV® (Lamivudine) Norditropin® (Somatropin) Hepsera® (Adefovir dipivoxil) PULMONARY ARTERIAL ® HYPERTENSION Novarel (Chorionic Gonadotropin) Lamivudine ® Adcirca® (Tadalafil) Nutropin AQ (Somatropin) Tenofovir disoproxil fumerate ® ® Revatio® (Sildenafil) Omnitrope (Somatropin) Vemlidy (Tenofovir alafenamide) ® ® Sildenafil Saizen (Somatropin) Viread (Tenofovir disoproxil Serostim® (Somatropin fumarate) DERMATOLOGY Zorbtive® (Somatropin) HEPATITIS C ATOPIC DERMATITIS METABOLISM DISORDER Daklinza® (Daclatasvir) Dupixent® (Dupilumab) Aldurazyme® (Laronidase) £ Epclusa® (Sofosbuvir/Velpatasvir) Buphenyl® (Sodium phenylbutyrate) Harvoni® (Ledipasvir/Sofosbuvir) HIDRADENITIS SUPPURATIVA ® £ ® ® Cerezyme (Imiglucerase) Intron A (Interferon alfa-2b) Humira (Adalimumab) ® £ Elaprase (Idursulfase) Ledipasvir/Sofosbuvir PLAQUE PSORIASIS Elelyso® (Taliglucerase alfa) £ Mavyret® (Glecaprevir/Pibrentasvir) ® Cimzia (Certolizumab pegol) Fabrazyme® (Agalsidase beta) £ Olysio® (Simeprevir) ® Cosentyx (Secukinumab) Kanuma® (Sebelipase alfa) Pegasys® (Peginterferon alfa-2a) ® Enbrel (Etanercept) Kuvan® (Sapropterin PegIntron® (Peginterferon alfa-2b) ® Humira (Adalimumab) dihydrochloride) Rebetol® (Ribavirin) ® Otezla (Apremilast) Lumizyme® (Alglucosidase alfa) Ribasphere® (Ribavirin) ® Remicade (Infliximab) £ Naglazyme® (Galsulfase) Riba-Pak® (Ribavirin) RenflexisTM (Infliximab-abda) £ Vimizim® (Elosulfase alfa) Ribavirin Stelara® (Ustekinumab) Vpriv® (Velaglucerase alfa) Sofosbuvir/Velpatasvir Taltz® (Ixekizumab) ® OSTEOPOROSIS Sovaldi (Sofosbuvir) ® ™ Tremfya (Guselkumab) ® Technivie (Ombitasvir/ Forteo (Teriparatide) Prolia® (Denosumab) Paritaprevir/ Ritonavir) ™ ENDOCRINOLOGY TYMLOS® (Abaloparatide) Viekira Pak (Ombitasvir/ Paritaprevir/ Ritonavir; Dasabuvir) ACROMEGALY Viekira XR™ Ombitasvir/ Octreotide acetate GASTROENTEROLOGY Paritaprevir/ Ritonavir/ Dasabuvir) Sandostatin® (Octreotide acetate) CROHN’S DISEASE/ Vosevi® (Sofosbuvir/Velpatasvir/ Sandostatin LAR® (Octreotide ULCERATIVE COLITIS ® Voxilaprevir) acetate) Cimzia (Certolizumab pegol) ® (Elbasvir/Grazoprevir) ® £ Zepatier ELECTROLYTE IMBALANCE Entyvio (Vedolizumab) ® Other Jadenu® (Deferasirox) Humira (Adalimumab) ® Doptelet® (Avatrombopag) ® Kineret (Anakinra) Veltassa (Patiromer) ® £ Remicade (Infliximab) TM (Infliximab-abda) £ Renflexis ® Simponi (Golimumab) ® Stelara (Ustekinumab) Last Updated: February 2019 unitypoint.org/specialty-pharmacy UnityPoint at Home Specialty Pharmacy Formulary This is a listing by therapy of specialty medications that UnityPoint at Home Specialty Pharmacy can provide or facilitate access to and is subject to change £Infusion Product – may be provided by UnityPoint at Home Infusion Pharmacy HEMATOLOGY HEMATOLOGY (cont’d) INFECTIOUS DISEASE (cont’d) HEMATOPOIETIC GROWTH HEMOPHILIA & RELATED HIV/AIDS (con’td) £ ® FACTORS DISORDERS (con’td) Crixivan (Indinavir sulfate) Aranesp® (Darbepoetin alfa) Kovaltry® (Antihemophilic Factor Descovy® (Emtricitabine/ Tenofovir) Epogen® (Epoetin alfa) (Recombinant) Didanosine Granix® (TBO Filgrastim) Monoclate-P® (Antihemophilic Edurant®(Rilpivirine) Leukine® (Sargramostim) factor) Egrifta® (Tesamorelin) Neulasta® (Pegfilgrastim) Novoeight® (Antihemophilic Factor) Emtriva® (Emtricitabine) Neupogen® (Filgrastim) Novoseven® RT (Coagulation Factor Entecavir Procrit® (Epoetin alfa) VIIa) Epivir® (Lamivudine) Promacta® (Eltrombopag) Nuwiq® (Human coagulation factor Epzicom® (Abacavir/ Lamivudine) Zarxio® (Filgrastim-sndz) VIII recombinant DNA, simoctocog Evotaz™ (Atazanavir/ Cobicistat) ® HEMOPHILIA & RELATED alfa) Fuzeon (Enfuvirtide) ® ® DISORDERS £ Profilnine (Factor IX Complex) Genvoya (Elvitegravir/ Cobicistat/ ® Advate® (Antihemophilic Factor Recombinate (Antihemophilic Emtricitabine/ Tenofovir (Recombinant)) Factor) alafenamide) ® ™ ® (Coagulation Factor IX) Afstyla (Antihemophilic Factor Rixubis Intelence (Entravirine) ® (recombinant), Single Chain Thrombate III (Antithrombin III) Invirase® (Saquinavir) ® ® Alphanate® (Antihemophilic Wilate (von Willebrand factor / Isentress (Raltegravir) factor/von Willebrand factor Coagulation Factor VIII complex) Juluca® (Dolutegravir/ Rilpivirine) ® ® Xyntha (Antihemophilic Factor) Kaletra (Lopinavir/ Ritonavir) complex) AlphaNine SD® (Coagulation Factor OTHER Lamivudine IX) Soliris® (Eculizumab) Lamivudine/Zidovudine ® Alprolix® (Coagulation Factor IX) RiaSTAP® (Fibrinogen Concentrate) Lexiva (Fosamprenavir) Bebulin® (Factor IX Complex) Lopinavir/ritonavir BeneFIX® (Coagulation Factor IX) INFECTIOUS DISEASE Nevirapine ® Norvir® (Ritonavir) Eloctate (Antihemophilic Factor/ HEPATITIS B / HEPATITIS C Odefsey® (Emtricitabine/ Rilpivirine/ Fc-Fusion Protein) *See Gastroenterology Section* Feiba NF® (Anti-Inhibitor Coagulant Tenofovir alafenamide) Complex) HIV/AIDS PREZCOBIX® (Darunavir/ Cobicistat) ® Helixate® FS (Antihemophilic Factor) Abacavir Prezista (Darunavir) ® Helimbra® (emicizumab-kxwh) Abacavir Sulfate/ Lamivudine/ Rescriptor (Dalavirdine mesylate) ® Hemofil M® (Antihemophilic Factor) Zidovudine Retrovir (Zidovudine) ® Humate-P® (Antihemophilic Abacavir/ Lamivudine Reyataz (Atazanavir) Factor/von Willebrand Factor Adefovir dipivoxil Selzentry® (Maraviroc) ® (VWF) Complex) Aptivus (Tipranavir) Stavudine ® ® Idelvion® (Coagulation Factor IX Atripla (Efavirenz/ Emtricitabine/ Stribild (Elvitegravir/ Cobicistat/ (Recombinant), Albumin fusion Tenofovir) Emtricitabine/tenofovir) ® protein) Biktarvy (Bictegravir/emtricitibine/ Sustiva® (Efavirenz) ® tenofovir alafenamide) ® (Antihemophilic Factor) Tivicay (Dolutegravir) Koāte -DVI ® ® Combivir (Lamivudine/ Zidovudine) ® (Antihemophilic Triumeq (Abacavir/ Dolutegravir/ Kogenate FS ® Factor) Complera (Emtricitabine/ Lamivudine) Rilpivirine/ tenofovir) Last Updated: February 2019 unitypoint.org/specialty-pharmacy UnityPoint at Home Specialty Pharmacy Formulary This is a listing by therapy of specialty medications that UnityPoint at Home Specialty Pharmacy can provide or facilitate access to and is subject to change £Infusion Product – may be provided by UnityPoint at Home Infusion Pharmacy INFECTIOUS DISEASE (cont’d) NEUROLOGY PULMONOLOGY (cont’d) HIV/AIDS (con’td) BOTULINUM TOXINS HEREDITARY ANGIOEDEMA Trizivir® (Abacavir/ Lamivudine/ Botox® (OnabotulinumtoxinA) Firazyr® (Icatibant) Zidovudine) Myobloc® (RimabotulinumtoxinB) Kalbitor® (Ecallantide) Truvada® (Emtricitabine/ Tenofovir) Xeomin® (IncobotulinumtoxinA) ® PULMONARY ARTERIAL Tybost (Cobicistat) HYPERTENSION ® MIGRANE PREVENTION Valcyte (Valganciclovir Aimovig® (Erenumab) Adcirca® (Tadalafil) hydrochloride) ® ® (Fremanezumab) Revatio (Sildenafil) ® Ajovy VIDEX (Didanosine) ® (OnabotulinumtoxinA) Sildenafil ® Botox Viracept (Nelfinavir mesylate) ® (Galcanezumab) ® Emgality Viramune (Nevirapine) RHEUMATOLOGY Voriconazole MOVEMENT DISORDER ® ANKYLOSING SPONDYLITIS Zerit® (Stavudine) Austedo (Deutetrabenazine) Cimzia® (Certolizumab pegol) Ziagen® (Abacavir) Dalfampridine Tetrabenazine Cosentyx® (Secukinumab) Zidovudine ® Xadago® (Safinamide) Humira (Adalimumab) OTHER Simponi® (Golimumab) Dificid® (Fidoximicin) MULTIPLE SCLEROSIS ® CRYOPYRIN-ASSOCIATED Noxafil® (Posaconazole) Aubagio (Teriflunomide) Avonex® (Interferon beta-1a) PERIODIC SYNDROMES ® ® (Interferon beta-1b) Ilaris (Canakinumab) MEN’S / WOMEN’S HEALTH BETASERON Copaxone® (Glatiramer acetate) PSORIATIC ARTHRITIS HORMONE THERAPY ® ® ® Extavia (Interferon beta-1b) Cimzia (Certolizumab pegol) Eligard (Leuprolide acetate) Gilenya® (Fingolimod) Cosentyx® (Secukinumab) Firmagon® (Degarelix) Glatiramer acetate Enbrel® (Etanercept) Leuprolide acetate Glatopa® (Glatiramer acetate) Humira® (Adalimumab) Lupron DEPOT® (Leuprolide acetate) Rebif® (Interferon beta-1a) Otezla® (Apremilast) Makena® (Hydroxyprogesterone Tysabri® (Natalizumab) £ Simponi® (Golimumab) caproate) ® ® Stelara (Ustekinumab) Supprelin LA (Histrelin acetate) PULMONOLOGY ® (Ixekizumab) ® Taltz Synarel (Nafarelin acetate) Thyrogen® (Thyrotropin alfa) ASTHMA RHEUMATOID ARTHRITIS ® £ Trelstar® (Triptorelin pamoate) Cinqair (Reslizumab) Actemra® (Tocilizumab) ® Vantas® (Histrelin) Dupixent (Dupilumab) Cimzia® (Certolizumab pegol) ® Zoladex® (Goserelin acetate) Fasenra (Benralizumab) Enbrel® (Etanercept) Nucala® (Mepolizumab) ® Humira (Adalimumab) NEPHROLOGY CYSTIC FIBROSIS Kevzara® (Sarilumab) ® ® ANEMIA Bethkis (Tobramycin) Kineret (Anakinra) ® ® Aranesp® (Darbepoetin alfa) Kitabis Pak (Tobramycin) Olumiant (Baricitinib) ® ® ® Epoetin alfa) Pertzye (Pancrelipase) Orencia (Abatacept) Epogen ( ® ® Pulmozyme® (Dornase Alfa) Simponi (Golimumab) Procrit (Epoetin alfa) ® Tobramycin Simponi Aria (Golimumab) ELECTROLYTE IMBALANCE Xeljanz® (Tofacitinib) Jadenu® (Deferasirox) Veltassa® (Patiromer) Last Updated: February 2019 unitypoint.org/specialty-pharmacy UnityPoint at Home Specialty Pharmacy Formulary This is a listing by therapy of specialty medications that UnityPoint at Home Specialty Pharmacy can provide or facilitate access to and is subject to change £Infusion Product – may be provided by UnityPoint at Home Infusion Pharmacy RHEUMATOLOGY (cont’d) PEDIATRICS
Load more

Recommended publications
  • AUBAGIO* (Teriflunomide)
    AUBAGIO* (teriflunomide) * Bolded medications are the preferred products RATIONALE FOR INCLUSION IN PA PROGRAM Background Aubagio (teriflunomide) is indicated for relapsing multiple sclerosis. It is an anti-inflammatory immunomodulatory agent, which inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis. The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown, but may involve a reduction in the number of activated lymphocytes in the CNS (1). Regulatory Status FDA-approved indication: Aubagio is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease (1). The Aubagio label includes a boxed warning citing the risk of hepatotoxicity. Aubagio is contraindicated in patients with severe hepatic impairment. Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide. Concomitant use of Aubagio with other potentially hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months before initiation of Aubagio and monitor ALT levels at least monthly for six months after starting Aubagio. If drug induced liver injury is suspected, discontinue Aubagio and start an accelerated elimination procedure. Elimination of Aubagio can be accelerated by administration of cholestyramine or activated charcoal for 11 days (1). Aubagio also carries a boxed warning on the risk of teratogenicity.
    [Show full text]
  • Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease Policy Number: 2021D0048K Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Provider Administered Drugs – Site of Care Applicable Codes .......................................................................... 3 Background.................................................................................... 3 Community Plan Policy Benefit Considerations .................................................................. 3 • Intravenous Enzyme Replacement Therapy (ERT) Clinical Evidence ........................................................................... 4 for Gaucher Disease U.S. Food and Drug Administration ............................................. 6 Centers for Medicare and Medicaid Services ............................. 6 References ..................................................................................... 7 Policy History/Revision Information ............................................. 8 Instructions for Use ....................................................................... 8 Coverage Rationale See Benefit Considerations This policy refers to the following drug products, all of which are intravenous enzyme replacement therapies used in the treatment of Gaucher disease: Cerezyme® (imiglucerase) Elelyso® (taliglucerase) VPRIV® (velaglucerase)
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Ten Years of the Hunter Outcome Survey (HOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry Joseph Muenzer1, Simon A
    Muenzer et al. Orphanet Journal of Rare Diseases (2017) 12:82 DOI 10.1186/s13023-017-0635-z REVIEW Open Access Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry Joseph Muenzer1, Simon A. Jones2, Anna Tylki-Szymańska3, Paul Harmatz4, Nancy J. Mendelsohn5,6, Nathalie Guffon7, Roberto Giugliani8, Barbara K. Burton9, Maurizio Scarpa10,11, Michael Beck12, Yvonne Jangelind13, Elizabeth Hernberg-Stahl14, Maria Paabøl Larsen15,17, Tom Pulles16,18 and David A. H. Whiteman15* Abstract Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfatase. Disease- specific treatment is available in the form of enzyme replacement therapy with intravenous idursulfase (Elaprase®, Shire). Since 2005, the Hunter Outcome Survey (HOS) has collected real-world, long-term data on the safety and effectiveness of this therapy, as well as the natural history of MPS II. Individuals with a confirmed diagnosis of MPS II who are untreated or who are receiving/have received treatment with idursulfase or bone marrow transplant can be enrolled in HOS. A broad range of disease- and treatment-related information is captured in the registry and, over the past decade, data from more than 1000 patients from 124 clinics in 29 countries have been collected. Evidence generated from HOS has helped to improve our understanding of disease progression in both treated and untreated patients and has extended findings from the formal clinical trials of idursulfase. As a long-term, global, observational registry, various challenges relating to data collection, entry, and analysis have been encountered.
    [Show full text]
  • WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173059 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 9/26 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US20 17/024981 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 30 March 2017 (30.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/3 15,400 30 March 2016 (30.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/457,584 10 February 2017 (10.02.2017) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 15/473,994 30 March 2017 (30.03.2017) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: AMICUS THERAPEUTICS, INC.
    [Show full text]
  • Publications in Scientific Journals (Peer Reviewed) 1
    Last Updated July 2020 Publications in Scientific Journals (Peer Reviewed) 1. Eisengart JB, King KE, Shapiro EG, Whitley CB, Muenzer J. The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome. Mol Genet Metab Rep. 2019 Dec 20;22:100549. PMID: 32055445 2. Viskochil D, Clarke LA, Bay L, Keenan H, Muenzer J, Guffon N. Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry. Am J Med Genet A. 2019 Dec;179(12):2425-2432. PMID: 31639289 3. Clarke LA, Giugliani R, Guffon N, Jones SA, Keenan HA, Munoz-Rojas MV, Okuyama T, Viskochil D, Whitley CB, Wijburg FA, Muenzer J. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clin Genet. 2019 Clin Genet. 2019 Oct;96(4):281-289. PMID: 31194252 4. Taylor JL, Clinard K, Powell CM, Rehder C, Young SP, Bali D, Beckloff SE, Gehtland LM, Kemper AR, Lee S, Millington D, Patel HS, Shone SM, Woodell C, Zimmerman SJ, Bailey DB Jr, Muenzer J. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening. J Pediatr. 2019 Aug;211:193-200. PMID: 31133280 5. Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M; MPS Consensus Programme Steering Committee; MPS Consensus Programme Co-Chairs.
    [Show full text]
  • DOCTORAL THESIS Effects of Glucocorticoid Overload on Central
    DOCTORAL THESIS Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders Ahmad, Rabia Award date: 2013 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 “Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders” By Rabia Ahmad, BSc (Hons). A thesis submitted in partial fulfilment of the requirements for the degree of PhD Department of Life Sciences University of Roehampton 2013 Abstract Irregularities of the Hypothalamic Pituitary Adrenal (HPA) axis are implicated in stress-related mood disorders. The ensuing long-term elevations in circulating glucocorticoids are associated with neurobiological changes seen in depression. This thesis aims to identify some of the brain mechanisms by which exposure to chronic stress may lead to depression using a preclinical experimental approach.
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Cochrane Database of Systematic Reviews
    Fluphenazine decanoate (depot) and enanthate for schizophrenia Author Maayan, Nicola, Quraishi, Seema N, David, Anthony, Jayaswal, Aprajita, Eisenbruch, Maurice, Rathbone, John, Asher, Rosie, Adams, Clive E Published 2015 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD000307.pub2 Copyright Statement © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD000307. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/391173 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD000307. DOI: 10.1002/14651858.CD000307.pub2. www.cochranelibrary.com Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley
    [Show full text]
  • Booklet 4 Stimulants Preface
    4 STIMULANTS 4 STIMULANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking.
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]